EG22506A - Processes and intermediates for preparing anti-cancer compounds - Google Patents

Processes and intermediates for preparing anti-cancer compounds

Info

Publication number
EG22506A
EG22506A EG20000364A EG20000364A EG22506A EG 22506 A EG22506 A EG 22506A EG 20000364 A EG20000364 A EG 20000364A EG 20000364 A EG20000364 A EG 20000364A EG 22506 A EG22506 A EG 22506A
Authority
EG
Egypt
Prior art keywords
intermediates
processes
preparing anti
cancer compounds
cancer
Prior art date
Application number
EG20000364A
Other languages
English (en)
Inventor
Richard S Lehner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of EG22506A publication Critical patent/EG22506A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling
EG20000364A 1999-03-31 2000-03-27 Processes and intermediates for preparing anti-cancer compounds EG22506A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
EG22506A true EG22506A (en) 2003-03-31

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20000364A EG22506A (en) 1999-03-31 2000-03-27 Processes and intermediates for preparing anti-cancer compounds

Country Status (50)

Country Link
US (1) US6476040B1 (ru)
EP (1) EP1044969B1 (ru)
JP (2) JP3420549B2 (ru)
KR (2) KR100430210B1 (ru)
CN (2) CN100351242C (ru)
AP (2) AP1655A (ru)
AR (1) AR018705A1 (ru)
AT (1) ATE348098T1 (ru)
AU (2) AU781402B2 (ru)
BG (1) BG65194B1 (ru)
BR (1) BRPI0001486B8 (ru)
CA (2) CA2427221C (ru)
CO (1) CO5160273A1 (ru)
CR (1) CR6165A (ru)
CZ (1) CZ299426B6 (ru)
DE (1) DE60032275T2 (ru)
DK (1) DK1044969T3 (ru)
DZ (1) DZ3030A1 (ru)
EA (3) EA005892B1 (ru)
EE (1) EE04589B1 (ru)
EG (1) EG22506A (ru)
ES (1) ES2278578T3 (ru)
GE (1) GEP20022653B (ru)
GT (1) GT200000037A (ru)
HK (1) HK1029790A1 (ru)
HR (1) HRP20000182B1 (ru)
HU (1) HU227698B1 (ru)
ID (1) ID25427A (ru)
IL (2) IL168036A (ru)
IS (1) IS2468B (ru)
MA (1) MA25087A1 (ru)
MY (1) MY136270A (ru)
NO (2) NO321952B1 (ru)
NZ (2) NZ503683A (ru)
OA (1) OA11335A (ru)
PA (1) PA8491901A1 (ru)
PE (1) PE20001599A1 (ru)
PL (1) PL339330A1 (ru)
PT (1) PT1044969E (ru)
RS (1) RS49836B (ru)
SG (2) SG121687A1 (ru)
SK (1) SK287339B6 (ru)
SV (1) SV2002000047A (ru)
TN (1) TNSN00064A1 (ru)
TR (1) TR200000837A2 (ru)
TW (1) TW553939B (ru)
UA (2) UA80955C2 (ru)
UY (1) UY26086A1 (ru)
YU (1) YU13200A (ru)
ZA (1) ZA200001586B (ru)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (ru) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стойкий полиморф гидрохлорида n-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина, способ его получения (варианты) и фармацевтическое применение
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
EP1777218B1 (en) 2000-10-20 2008-12-31 Eisai R&D Management Co., Ltd. Process for the preparation of 4-phenoxy quinoline derivatives
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
CA2531327A1 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. Compounds and therapeutical use thereof
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
BRPI0414489A8 (pt) 2003-09-16 2019-01-15 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina
DK2210607T3 (da) 2003-09-26 2011-12-12 Exelixis Inc N-[3-fluor-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid til behandling af kræft
EP1683785B1 (en) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
NZ550796A (en) * 2004-05-06 2010-07-30 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
SI1859793T1 (sl) * 2005-02-28 2011-08-31 Eisai R&D Man Co Ltd Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
JPWO2007052849A1 (ja) * 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
JPWO2008001956A1 (ja) * 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝線維症治療剤
WO2008012105A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
US8372856B2 (en) * 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
AU2008205847A1 (en) 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
WO2008102369A1 (en) * 2007-02-21 2008-08-28 Natco Pharma Limited Novel polymorphs of erlotinib hydrochloride and method of preparation
CA2682013C (en) 2007-04-04 2015-06-30 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
US20090012295A1 (en) * 2007-06-25 2009-01-08 Ales Gavenda Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib
US8389531B2 (en) 2007-07-11 2013-03-05 Hetero Drugs Limited Process for erlotinib hydrochloride
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
MX2010002081A (es) * 2007-08-23 2010-06-01 Plus Chemicals Sa Procesos para la preparacion de formas a, b cristalinas y de la forma a cristalina pura de erlotinib hc1.
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
JP5638244B2 (ja) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質と抗腫瘍性白金錯体との併用
CN102036962B (zh) * 2008-01-29 2013-08-07 卫材R&D管理有限公司 血管生成抑制剂和紫杉烷的组合使用
WO2009121042A1 (en) * 2008-03-28 2009-10-01 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
KR20110017907A (ko) * 2008-07-07 2011-02-22 플러스 케미칼스, 에스.에이. 엘로티닙 염기 및 엘로티닙 ｈｃｌ의 결정형
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
WO2010083414A1 (en) 2009-01-16 2010-07-22 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer
CN102438995B (zh) 2009-03-26 2014-12-17 兰贝克赛实验室有限公司 厄洛替尼或其药学上可接受的盐的制备工艺
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
KR101677790B1 (ko) 2010-06-25 2016-11-18 에자이 알앤드디 매니지먼트 가부시키가이샤 키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제
WO2012028861A1 (en) 2010-07-23 2012-03-08 Generics [Uk] Limited Pure erlotinib
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
NZ630289A (en) 2012-09-04 2016-08-26 Shilpa Medicare Ltd Crystalline erlotinib hydrochloride process
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
RU2658601C2 (ru) 2013-05-14 2018-06-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
EP4089076A1 (en) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
RS65049B1 (sr) 2015-02-25 2024-02-29 Eisai R&D Man Co Ltd Metoda za suzbijanje gorčine derivata kinolina
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
CA2216796C (en) * 1995-03-30 2003-09-02 Pfizer Inc. Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
ES2194181T3 (es) 1996-02-13 2003-11-16 Astrazeneca Ab Derivados de quinazolina como inhibidores de vegf.
DK0885198T3 (da) 1996-03-05 2002-03-25 Astrazeneca Ab 4-Anilinoquinazolinderivater
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
ATE295839T1 (de) 1998-04-29 2005-06-15 Osi Pharm Inc N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethox )-4-chinazolinamin-mesylat-anhydrat und -monohydrat

Also Published As

Publication number Publication date
NO20054715L (no) 2000-10-02
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
KR20020084903A (ko) 2002-11-13
AP1265A (en) 2004-03-26
EE200000255A (et) 2000-12-15
PA8491901A1 (es) 2001-12-14
JP2003176274A (ja) 2003-06-24
ATE348098T1 (de) 2007-01-15
BG104278A (en) 2001-08-31
SG121687A1 (en) 2006-05-26
HUP0001353A2 (hu) 2001-05-28
CA2427221A1 (en) 2000-09-30
JP4074509B2 (ja) 2008-04-09
NO321952B1 (no) 2006-07-24
EA200000274A2 (ru) 2000-10-30
EA200000274A3 (ru) 2003-02-27
CA2427221C (en) 2008-09-16
EP1044969A3 (en) 2000-11-29
IL135245A0 (en) 2001-05-20
BG65194B1 (bg) 2007-06-29
SK287339B6 (sk) 2010-07-07
HU0001353D0 (en) 2000-06-28
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
CN1215061C (zh) 2005-08-17
AP1655A (en) 2006-09-01
TR200000837A2 (tr) 2000-11-21
PT1044969E (pt) 2007-05-31
CN100351242C (zh) 2007-11-28
CO5160273A1 (es) 2002-05-30
CR6165A (es) 2008-10-10
EA004654B1 (ru) 2004-06-24
US6476040B1 (en) 2002-11-05
ES2278578T3 (es) 2007-08-16
HRP20000182A2 (en) 2001-04-30
GT200000037A (es) 2001-09-21
CZ20001155A3 (cs) 2001-03-14
HU227698B1 (en) 2011-12-28
PL339330A1 (en) 2000-10-09
UA80955C2 (en) 2007-11-26
TW553939B (en) 2003-09-21
CA2302965A1 (en) 2000-09-30
BRPI0001486B8 (pt) 2021-05-25
UA70928C2 (ru) 2004-11-15
CA2302965C (en) 2004-02-17
AR018705A1 (es) 2001-11-28
SV2002000047A (es) 2002-01-23
JP2000290262A (ja) 2000-10-17
NO20001648D0 (no) 2000-03-30
RS49836B (sr) 2008-08-07
NZ512818A (en) 2003-01-31
EP1044969B1 (en) 2006-12-13
DE60032275D1 (de) 2007-01-25
KR100430210B1 (ko) 2004-05-03
AU2005201494A1 (en) 2005-05-05
SK4442000A3 (en) 2000-10-09
IS5411A (is) 2000-10-02
DE60032275T2 (de) 2007-07-12
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
GEP20022653B (en) 2002-03-25
IS2468B (is) 2008-12-15
NZ503683A (en) 2001-09-28
EP1044969A2 (en) 2000-10-18
NO20001648L (no) 2000-10-02
BR0001486A (pt) 2001-05-02
HK1029790A1 (en) 2001-04-12
AU781402B2 (en) 2005-05-19
UY26086A1 (es) 2000-10-31
SG115536A1 (en) 2005-10-28
ID25427A (id) 2000-10-05
YU13200A (sh) 2002-10-18
DZ3030A1 (fr) 2004-03-27
MY136270A (en) 2008-09-30
CN1276370A (zh) 2000-12-13
OA11335A (en) 2003-12-10
EA005892B1 (ru) 2005-06-30
MA25087A1 (fr) 2000-10-01
CN1699350A (zh) 2005-11-23
HUP0001353A3 (en) 2002-01-28
EA200201245A1 (ru) 2003-04-24
ZA200001586B (en) 2001-10-01
CZ299426B6 (cs) 2008-07-23
KR100430209B1 (ko) 2004-05-03
EE04589B1 (et) 2006-02-15
AU2005201494B2 (en) 2008-02-07
JP3420549B2 (ja) 2003-06-23
EA200201244A1 (ru) 2003-04-24
KR20010014658A (ko) 2001-02-26
EA005561B1 (ru) 2005-04-28
DK1044969T3 (da) 2007-04-23
BRPI0001486B1 (pt) 2019-01-29
PE20001599A1 (es) 2001-01-18

Similar Documents

Publication Publication Date Title
EG22506A (en) Processes and intermediates for preparing anti-cancer compounds
AP2003002757A0 (en) Process and intermediates for preparing anticancer compounds
IL145798A0 (en) Fap-activated anti-tumor compounds
EP1140083A4 (en) NEW CONNECTIONS
HUP0200448A3 (en) Processes for preparing pesticidal intermediates
GB9930390D0 (en) Releasable fasteners
EG24063A (en) Novel compounds
IL149007A0 (en) Pentacyclic taxane compounds
GB9924855D0 (en) Novel processes
IL146054A0 (en) Processes for preparing pesticidal intermediates
GB0121486D0 (en) Processes for the preparation of Α-Aminoketones
HUP0202865A3 (en) Process for the preparation of 2-cyanopyridines
IL138691A (en) Process for the preparation of 3-acyl-indoles
GB9923024D0 (en) Lap top extension
HUP0000559A3 (en) Process for preparing cyanoaceticacidesters
EP1242378A4 (en) NEW PROCEDURES
TW382910U (en) Structural improvement for the physique of the clog
GB0001064D0 (en) Structure for positioning stationery
IL140300A0 (en) Process for the preparation of amides
HU9904575D0 (en) Process for preparation of n-alkoxy-methyl-acidamides
TW404191U (en) Structure improvement for pendants
TW377550U (en) Improvement for grass-planting brick
HUP0201518A3 (en) Process for the preparation of tetrafluorohalogenbenzenes
TW385647U (en) Structure for ring
PL343301A1 (en) Fastening means